CPC C07K 16/2863 (2013.01) [A61P 35/00 (2018.01); C07K 14/00 (2013.01); C07K 14/71 (2013.01); C07K 16/22 (2013.01); C07K 16/2803 (2013.01); C07K 16/2818 (2013.01); C07K 16/2827 (2013.01); C07K 16/468 (2013.01); A61K 2039/505 (2013.01); C07K 2317/31 (2013.01); C07K 2317/565 (2013.01); C07K 2317/622 (2013.01); C07K 2317/64 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01); C07K 2318/10 (2013.01); C07K 2319/30 (2013.01); C07K 2319/32 (2013.01)] | 6 Claims |
1. A bispecific antibody comprising two heavy chains and two light chains, wherein each heavy chain comprises, from N-terminus to C-terminus, a VH domain, a CHI domain, a CH2 domain, a CH3 domain, a peptide linker and a TGF-ß1 RII extracellular domain (ECD), wherein each light chain comprises, from N-terminus to C-terminus, a VL domain and a CL domain, wherein the VH domain comprises the amino acid sequence of SEQ ID NO:90 or 96, wherein the VL domain comprises the amino acid sequence of SEQ ID NO:91, wherein the bispecific antibody binds specifically to (1) human VEGF-A through the VH and VL domains and (2) human TGFß1 through the TGF-ß1 RII extracellular domain (ECD), wherein the TGF-ß1 R11 ECD comprises the amino acid sequence of SEQ ID NO:89.
|